Furthermore, they underscore the potential of UBA7 as a biomarker to stratify SF3B1-mutant MDS and CLL patients, offering a refined approach for risk assessment and highlighting opportunities for targeted therapeutic interventions. This evidence concerns the gene UBA7 and B-cell chronic lymphocytic leukemia.